Is Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) a Buy? The Stock Reported Less Sellers | Thorold News

The stock of Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) registered a decrease of 0.22% in short interest. ETTX’s total short interest was 45,800 shares in March as published by FINRA. Its down 0.22% from 45,900 shares, reported previously. With 21,300 shares average volume, it will take short sellers 2 days to cover their ETTX’s short positions.

The stock increased 2.22% or $0.15 during the last trading session, reaching $6.95. About 1,959 shares traded. Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) has 0.00% since March 15, 2018 and is . It has underperformed by 4.37% the SP500.

Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. The company has market cap of $91.06 million. It is involved in developing ETX2514SUL, a novel

... read more at: